Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$10.38 -0.9%	$9.03	$3.17 ▼ $10.87	$1.59B	1.8	1.57 million shs	1.77 million shs
AMPH Amphastar Pharmaceuticals	$24.56 -3.1%	$24.77	$22.64 ▼ $53.96	$1.19B	0.77	491,996 shs	672,732 shs
CRLBF Cresco Labs	$0.43 -10.1%	$0.67	$0.43 ▼ $2.05	$235.69M	1.47	672,738 shs	494,321 shs
SNDX Syndax Pharmaceuticals	$9.48 -2.2%	$11.10	$8.58 ▼ $25.07	$833.80M	0.74	1.81 million shs	2.64 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-0.86%	+0.58%	+14.19%	+23.57%	+237.01%
AMPH Amphastar Pharmaceuticals	-3.08%	-4.88%	+1.66%	-13.18%	-38.68%
CRLBF Cresco Labs	-10.08%	-13.33%	-37.26%	-40.88%	-72.96%
SNDX Syndax Pharmaceuticals	-2.17%	-7.51%	-10.99%	-30.85%	-50.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.5692 of 5 stars	1.4	1.0	4.2	2.0	2.5	0.6
AMPH Amphastar Pharmaceuticals	4.2255 of 5 stars	3.1	1.0	3.7	2.7	4.2	1.3
CRLBF Cresco Labs	0.4053 of 5 stars	0.0	3.0	0.0	0.6	0.0	1.3
SNDX Syndax Pharmaceuticals	3.0648 of 5 stars	3.5	0.0	4.4	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	1.84% Upside
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	31.65% Upside
CRLBF Cresco Labs	3.00	Buy	N/A	N/A
SNDX Syndax Pharmaceuticals	2.91	Moderate Buy	$35.91	278.79% Upside

Current Analyst Ratings Breakdown

Latest CRLBF, AMPH, SNDX, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/3/2025	CRLBF Cresco Labs	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Moderate Buy
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/6/2025	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $17.00
5/6/2025	SNDX Syndax Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00
5/2/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/21/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00 ➝ $9.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	8.81	N/A	N/A	$1.37 per share	7.58
AMPH Amphastar Pharmaceuticals	$731.97M	1.58	$4.85 per share	5.06	$15.23 per share	1.61
CRLBF Cresco Labs	$724.34M	0.29	N/A	N/A	$0.79 per share	0.55
SNDX Syndax Pharmaceuticals	$23.68M	34.45	N/A	N/A	$3.38 per share	2.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	8.90	7.47	6.60	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
CRLBF Cresco Labs	-$74.44M	-$0.24	N/A	N/A	N/A	-11.86%	-21.77%	-6.00%	8/6/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-757.53%	-101.60%	-58.41%	8/7/2025 (Estimated)

Latest CRLBF, AMPH, SNDX, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q1 2025	CRLBF Cresco Labs	-$0.03	-$0.04	-$0.01	-$0.04	$164.37 million	$165.76 million
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRLBF Cresco Labs	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
CRLBF Cresco Labs	1.63	2.75	1.98
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
AMPH Amphastar Pharmaceuticals	65.09%
CRLBF Cresco Labs	0.05%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
AMPH Amphastar Pharmaceuticals	27.50%
CRLBF Cresco Labs	N/A
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.18 million	Optionable
CRLBF Cresco Labs	2,900	491.02 million	N/A	Not Optionable
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable

CRLBF, AMPH, SNDX, and ADPT Headlines

Recent News About These Companies

Syndax reports publication of revumenib data from BEAT AML trial

June 13, 2025 | msn.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Assenagon Asset Management S.A.

June 13, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7% - Time to Sell?

June 12, 2025 | marketbeat.com

Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj

June 12, 2025 | thepharmaletter.com

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

June 12, 2025 | globenewswire.com

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

June 12, 2025 | globenewswire.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

June 7, 2025 | marketbeat.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

June 5, 2025 | globenewswire.com

Ameriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

June 5, 2025 | marketbeat.com

Kura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With Syndax

June 3, 2025 | biospace.com

Nuveen Asset Management LLC Trims Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

June 1, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DE

June 1, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLP

May 31, 2025 | marketbeat.com

Voloridge Investment Management LLC Takes $1.05 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 31, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 4.9% - Still a Buy?

May 30, 2025 | marketbeat.com

Syndax Announces Participation in June Investor Conferences

May 29, 2025 | globenewswire.com

Polar Asset Management Partners Inc. Invests $1.12 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 29, 2025 | marketbeat.com

Millennium Management LLC Has $7.76 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 28, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages

May 28, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LP

May 27, 2025 | marketbeat.com

Two Sigma Advisers LP Has $7.09 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRLBF, AMPH, SNDX, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$10.38 -0.09 (-0.86%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$10.12 -0.27 (-2.55%)

As of 06/20/2025 07:52 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Amphastar Pharmaceuticals NASDAQ:AMPH

$24.56 -0.78 (-3.08%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$24.56 0.00 (0.00%)

As of 06/20/2025 06:13 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Cresco Labs OTCMKTS:CRLBF

$0.43 -0.05 (-10.08%)

As of 06/20/2025 03:59 PM Eastern

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.

Syndax Pharmaceuticals NASDAQ:SNDX

$9.48 -0.21 (-2.17%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.48 -0.01 (-0.05%)

As of 06/20/2025 06:41 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time